Page last updated: 2024-11-10

thiocarlide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3001386
CHEMBL ID214920
CHEBI ID135637
SCHEMBL ID329833
MeSH IDM0262937

Synonyms (59)

Synonym
unii-43m23x81y2
disocarban
datanil
tiocarlida
tiocarlide [inn:ban:dcf]
nsc 742400
tiocarlidum
4-13-00-01187 (beilstein handbook reference)
43m23x81y2 ,
carbanilide, 4,4'-bis(isopentyloxy)thio-
brn 2546347
tiocarlid
einecs 213-006-5
tiocarlidum [inn-latin]
tiocarlida [inn-spanish]
4,4'-diisoamyloxythiocarbanilide
n,n'-bis(4-(3-methylbutoxy)phenyl)thiourea
4,4'-bis(isopentyloxy)thiocarbanilide
datc
D07246
tiocarlide (inn)
isoxyl
thiourea, n,n'-bis(4-(3-methylbutoxy)phenyl)-
nsc742400
1,3-bis(4-isopentyloxyphenyl)thiourea
amixyl
brn2546347
thiocarlide
910-86-1
disoxyl
tiocarlide
CHEMBL214920
dat-c
1,3-bis[4-(3-methylbutoxy)phenyl]thiourea
nsc-742400
thiourea,n'-bis[4-(3-methylbutoxy)phenyl]-
bdbm50351209
FT-0603523
SCHEMBL329833
smr004701761
MLS006010834
tiocarlide [who-dd]
tiocarlide [mi]
tiocarlide [mart.]
tiocarlide [inn]
thiourea, n,n'-bis[4-(3-methylbutoxy)phenyl]-
BWBONKHPVHMQHE-UHFFFAOYSA-N
n,n'-bis[4-(isopentyloxy)phenyl]thiourea #
4,4'-bis(isoamyloxy)thiocarbanilide
HMS3650A11
AKOS028111658
DTXSID70238358
SR-01000872619-2
sr-01000872619
CHEBI:135637
1,3-bis(4-(isopentyloxy)phenyl)thiourea
DB13608
SR-01000872619-3
Q7784652

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Isoxyl microparticles and controls in concentrations up to 100microg/ml were not toxic to macrophages."( Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency.
Hickey, AJ; Wang, C, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydrolase, alpha/beta hydrolase fold familyMycobacterium tuberculosis CDC1551IC50 (µMol)0.02200.02200.02200.0220AID613885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID613894Antituberculosis activity against Mycobacterium smegmatis MC2 155 after 7 days by microbroth dilution method2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID374301Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 25618 overexpressing ethA gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1459568Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID613882Inhibition of Mycobacterium tuberculosis recombinant EphB expressed in Escherichia coli BL21 using CMNPC as substrate at 10 nM after 30 mins by fluorescent assay relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID283669Antimycobacterial activity against Mycobacterium bovis BCG Pasteur with pMV261 vector2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID374306Antimycobacterial activity against Mycobacterium tuberculosis isolate Mt103 overexpressing ethR gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374319Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG Pasteur 1173P2 sonicates assessed as inhibition of alphamycolates production by autoradiography2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374307Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R22 mutant expressing VV16 plasmid by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374310Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R33 mutant expressing VV16 plasmid by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID383500Antitubercular activity against Mycobacterium bovis BCG2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID374305Antimycobacterial activity against Mycobacterium tuberculosis isolate Mt103 overexpressing ethA gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID283672Drug metabolizing activity of Mycobacterium bovis BCG recombinant ethA expressed in Escherichia coli2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID613881Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID283671Antimycobacterial activity against Mycobacterium bovis BCG str. Pasteur 1173P2 overexpressing ethA gene2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID374312Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R33 mutant overexpressing ethR gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID270354Selectivity index, IC50 against Vero cells/MIC against Mycobacterium2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.
AID383502Antitubercular activity against Mycobacterium aurum A12008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID374321Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane and partially purified EthA as cofactors assessed as oleic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID613895Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID283667Inhibition of oleic acid synthesis in Mycobacterium bovis BCG NCTC 5692 assessed as incorporation of [2-14C]acetate2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID283668Inhibition of oleic acid synthesis in Mycobacterium bovis BCG NCTC 5692 with ethR-knockout mutant assessed as incorporation of [2-14C]acetate2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID143878Antibacterial activity against Mycobacterium bovis (BCG); value ranges from 0.5-12004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG.
AID613880Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 7 days by microbroth dilution method2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID374328Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane as cofactor assessed as tuberculostearic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374324Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane as cofactor assessed as palmitoleic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID613886Antibacterial activity against Enterococcus faecium2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID374326Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane as cofactor assessed as oleic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374311Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R33 mutant overexpressing ethA gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID613887Antibacterial activity against Enterococcus faecalis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID283666Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG NCTC 5692 assessed as incorporation of [2-14C]acetate2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID374322Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane and partially purified EthA as cofactors assessed as stearic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID374325Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane as cofactor assessed as palmitic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1459565Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1459564Antimycobacterial activity against Mycobacterium smegmatis MC2 155 after 48 hrs by serial dilution method
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID383501Antitubercular activity against Mycobacterium avium2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID613889Antibacterial activity against Staphylococcus aureus2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID374308Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R22 mutant overexpressing ethA gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374300Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 25618 expressing VV16 plasmid by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID270353Inhibition of oleate production in Mycobacterium bovis BCG2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID374320Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane and partially purified EthA as cofactors assessed as palmitic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374302Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane and partially purified EthA as cofactors assessed as palmitoleic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID613893Antibacterial activity against Klebsiella pneumoniae2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613890Antibacterial activity against Escherichia coli expressing TolC2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613884Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate after 10 mins by fluorescent assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID613870Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by microplate alamar blue assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis, antitubercular activity, and SAR study of N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID374323Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane and partially purified EthA as cofactors assessed as tuberculostearic acid levels relative control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374318Ratio of MIC for Mycobacterium tuberculosis H37Rv overexpressing ethR gene to MIC for wild-type Mycobacterium tuberculosis H37Rv expressing VV16 plasmid2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID613891Antibacterial activity against Escherichia coli K122011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID744646Antimycobacterial activity against Mycobacterium avium 724 assessed as growth inhibition after 12 days microdrop agar proportion test2013European journal of medicinal chemistry, May, Volume: 63Efficient synthesis of new (R)-2-amino-1-butanol derived ureas, thioureas and acylthioureas and in vitro evaluation of their antimycobacterial activity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID374303Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 25618 overexpressing ethR gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID283670Antimycobacterial activity against Mycobacterium bovis BCG str. Pasteur 1173P2 overexpressing ethR gene2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1459577Cytotoxicity against Balb/c mouse peritoneal macrophages assessed as reduction in cell viability after 48 hrs by MTT assay
AID383499Antitubercular activity against Mycobacterium tuberculosis H37Rv2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID374330Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG Pasteur 1173P2 sonicates assessed as inhibition of alphamycolates production using partially purified EthA as cofactor by autoradiography2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID374329Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG Pasteur 1173P2 sonicates assessed as inhibition of ketomycolates production by autoradiography2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID502043Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATTC 27294 by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Design, synthesis, and in vitro antiprotozoal, antimycobacterial activities of N-{2-[(7-chloroquinolin-4-yl)amino]ethyl}ureas.
AID374331Inhibition of mycolic acid synthesis in Mycobacterium bovis BCG Pasteur 1173P2 sonicates assessed as inhibition of ketomycolates production using partially purified EthA as cofactor by autoradiography2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID270352Antibacterial activity against Mycobacterium bovis BCG2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.
AID374304Antimycobacterial activity against Mycobacterium tuberculosis isolate Mt103 expressing VV16 plasmid by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID613888Antibacterial activity against Bacillus anthracis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613892Antibacterial activity against Pseudomonas aeruginosa2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID374309Antimycobacterial activity against Mycobacterium tuberculosis MT1K ISO-R22 mutant overexpressing ethR gene by colorimetric resazurin microtiter assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID374317Ratio of MIC for wild-type Mycobacterium tuberculosis H37Rv expressing VV16 plasmid to MIC for Mycobacterium tuberculosis H37Rv overexpressing ethA gene2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID374327Inhibition of Mycobacterium tuberculosis H37Rv recombinant DesA3-mediated unsaturated fatty acid synthesis using Mycobacterium smegmatis MC2155 membrane as cofactor assessed as stearic acid levels relative to control2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.
AID744645Antimycobacterial activity against Mycobacterium aurum A+ assessed as growth inhibition after 4 days microdrop agar proportion test2013European journal of medicinal chemistry, May, Volume: 63Efficient synthesis of new (R)-2-amino-1-butanol derived ureas, thioureas and acylthioureas and in vitro evaluation of their antimycobacterial activity.
AID283663Antimycobacterial activity against Mycobacterium bovis BCG NCTC 56922007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID327999Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
N-D-aldopentofuranosyl-N'-[p-(isoamyloxy)phenyl]-thiourea derivatives: potential anti-TB therapeutic agents.
AID613885Inhibition of Mycobacterium tuberculosis recombinant EphE expressed in Escherichia coli BL21 using CMNPC as substrate after 30 mins by fluorescent assay relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID283664Antimycobacterial activity against Mycobacterium bovis BCG NCTC 5692 with ethR-knockout mutant2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.
AID270351Antibacterial activity against Mycobacterium tuberculosis H37Rv2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.
AID1459567Antimycobacterial activity against Mycobacterium tuberculosis MC2 6030 after 2 to 3 weeks by agar plate method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (137)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990114 (83.21)18.7374
1990's1 (0.73)18.2507
2000's8 (5.84)29.6817
2010's13 (9.49)24.3611
2020's1 (0.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.23 (24.57)
Research Supply Index5.15 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (6.83%)5.53%
Reviews6 (3.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other144 (89.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]